Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Heart Test Laboratories, Inc. (HSCS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0000-0.2400 (-10.71%)
At close: 04:00PM EDT
1.9800 -0.02 (-1.00%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2400
Open2.2500
Bid1.9000 x 2200
Ask2.0900 x 1000
Day's Range1.9900 - 2.8700
52 Week Range1.1500 - 6.0000
Volume2,608,348
Avg. Volume1,718,342
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results

    MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS Southlake, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- – Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve a

  • GlobeNewswire

    HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th

    Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness, today announced that Andrew Simpson, CEO, and Chairman of HeartSciences, will be participating in the Benzinga All Access event taking place on July 15, 2022. Mr. Simpson is scheduled to present on Friday, July 15, 2022,

  • GlobeNewswire

    Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing

    SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness, today announced the pricing of its initial public offering of 1,500,000 units, each consisting of one share of common stock (the “Common Stock”) and a warrant (the “Warrants”) to purchase one sha

Advertisement
Advertisement